167 related articles for article (PubMed ID: 32323788)
1. Epigenetic control of the EWS‑FLI1 promoter in Ewing's sarcoma.
Montoya C; Rey L; Rodríguez J; Fernández MJ; Troncoso D; Cañas A; Moreno O; Henríquez B; Rojas A
Oncol Rep; 2020 Apr; 43(4):1199-1207. PubMed ID: 32323788
[TBL] [Abstract][Full Text] [Related]
2. Promiscuous partnerships in Ewing's sarcoma.
Sankar S; Lessnick SL
Cancer Genet; 2011 Jul; 204(7):351-65. PubMed ID: 21872822
[TBL] [Abstract][Full Text] [Related]
3. The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.
Vural C; Uluoğlu O; Akyürek N; Oğuz A; Karadeniz C
Pathol Oncol Res; 2011 Sep; 17(3):619-25. PubMed ID: 21267687
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA‑34b promotes proliferation, migration and invasion of Ewing's sarcoma cells by downregulating Notch1.
Lu Q; Lu M; Li D; Zhang S
Mol Med Rep; 2018 Oct; 18(4):3577-3588. PubMed ID: 30106161
[TBL] [Abstract][Full Text] [Related]
5. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.
Yuan B; Ji W; Xia H; Li J
Mol Med Rep; 2018 Mar; 17(3):4291-4298. PubMed ID: 29328472
[TBL] [Abstract][Full Text] [Related]
6. Identification of a New Transcriptional Co-Regulator of STEAP1 in Ewing's Sarcoma.
Markey FB; Romero B; Parashar V; Batish M
Cells; 2021 May; 10(6):. PubMed ID: 34073779
[TBL] [Abstract][Full Text] [Related]
7. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.
Sankar S; Theisen ER; Bearss J; Mulvihill T; Hoffman LM; Sorna V; Beckerle MC; Sharma S; Lessnick SL
Clin Cancer Res; 2014 Sep; 20(17):4584-97. PubMed ID: 24963049
[TBL] [Abstract][Full Text] [Related]
8. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
[TBL] [Abstract][Full Text] [Related]
9. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
Kinsey M; Smith R; Lessnick SL
Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
[TBL] [Abstract][Full Text] [Related]
10. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
[TBL] [Abstract][Full Text] [Related]
11. [Ewing's tumours, genetic and cellular aspects].
Delattre O
Pathol Biol (Paris); 2008 Jul; 56(5):257-9. PubMed ID: 18485618
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.
Svoboda LK; Harris A; Bailey NJ; Schwentner R; Tomazou E; von Levetzow C; Magnuson B; Ljungman M; Kovar H; Lawlor ER
Epigenetics; 2014 Dec; 9(12):1613-25. PubMed ID: 25625846
[TBL] [Abstract][Full Text] [Related]
13. Development of an Ewing sarcoma cell line with resistance to EWS‑FLI1 inhibitor YK‑4‑279.
Conn E; Hour S; Allegakoen D; Graham G; Petro J; Kouassi-Brou M; Hong SH; Selvanathan S; Çelik H; Toretsky J; Üren A
Mol Med Rep; 2020 Mar; 21(3):1667-1675. PubMed ID: 32016454
[TBL] [Abstract][Full Text] [Related]
14. Ewing's sarcoma of the cervix: A case report and review of literature.
Zhang Y; Nong W; Ren Y; Jiang J; Zhang H; Meng L; Li Q; Zhang Q; Wang X; Wang Y; Liu C; Li F
Histol Histopathol; 2020 May; 35(5):475-480. PubMed ID: 31688946
[TBL] [Abstract][Full Text] [Related]
15. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
[TBL] [Abstract][Full Text] [Related]
16. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I
Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423
[TBL] [Abstract][Full Text] [Related]
17. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
18. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.
Yang L; Hu HM; Zielinska-Kwiatkowska A; Chansky HA
Biochem Biophys Res Commun; 2010 Nov; 402(1):129-34. PubMed ID: 20933505
[TBL] [Abstract][Full Text] [Related]
19. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma.
Sheffield NC; Pierron G; Klughammer J; Datlinger P; Schönegger A; Schuster M; Hadler J; Surdez D; Guillemot D; Lapouble E; Freneaux P; Champigneulle J; Bouvier R; Walder D; Ambros IM; Hutter C; Sorz E; Amaral AT; de Álava E; Schallmoser K; Strunk D; Rinner B; Liegl-Atzwanger B; Huppertz B; Leithner A; de Pinieux G; Terrier P; Laurence V; Michon J; Ladenstein R; Holter W; Windhager R; Dirksen U; Ambros PF; Delattre O; Kovar H; Bock C; Tomazou EM
Nat Med; 2017 Mar; 23(3):386-395. PubMed ID: 28134926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
